Athira cuts 70% of workforce, pivots to ATH-1105 after LIFT-AD readout

LeonaBio, Inc.

Workforce reduction of ~70% (49 positions); one-time costs ~$2.8M third-quarter 2024.
Annualized cost savings ~$13.4M; cash runway extended into Q1 2026.
CFO Andrew Gengos and COO Rachel Lenington terminated without cause, effective Oct 1, 2024.
VP Finance Robert Renninger appointed principal financial and accounting officer.
Focus shifts to ATH-1105 (oral HGF modulator) for ALS; Phase 1 completes by year-end 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.